Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review

被引:462
作者
Delvigne, A [1 ]
Rozenberg, S [1 ]
机构
[1] Free Univ Brussels, IVF Ctr, Dept Obstet & Gynaecol, St Peter Hosp, B-1000 Brussels, Belgium
关键词
coasting; IVF; OHSS; prevention; treatment;
D O I
10.1093/humupd/8.6.559
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy. Fortunately, the reported prevalence of the severe form of OHSS is small, ranging from 0.5 to 5%. Nevertheless, as this is an iatrogenic complication of a non-vital treatment with a potentially fatal outcome, the syndrome remains a serious problem for specialists dealing with infertility. The aim of this literature review was to determine whether it is possible to identify patients at risk, and which preventive method should be applied when an exaggerated ovarian response occurs. Data pertaining to the epidemiology and prevention of OHSS in women were searched using Medline, Current Contents and PubMed, and are summarized. Preventive strategies attempt either to limit the dose or concentration of hCG or to find a way to induce luteolysis without inducing a detrimental effect on endometrial and oocyte quality. The following particular preventive strategies were reviewed: cancelling the cycle; coasting; early unilateral ovarian follicular aspiration (EUFA); modifying the methods of ovulation triggering; administration of glucocorticoids, macromolecules and progesterone; cryopreservation of all embryos; and electrocautery or laser vaporization of one or both ovaries.
引用
收藏
页码:559 / 577
页数:19
相关论文
共 189 条
[91]  
HANING RV, 1983, FERTIL STERIL, V40, P31
[92]  
Hazout A, 1984, GYNECOLOGIE, V66, P220
[93]   Efficacy and safety of recombinant follicle stimulating hormone (Puregon(R)) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: A prospective, randomized, assessor-blind, multicentre trial [J].
Hedon, B ;
Out, HJ ;
Hugues, JN ;
Camier, B ;
Cohen, J ;
Lopes, P ;
Zorn, JR ;
vanderHeijden, B ;
Bennink, HJTC .
HUMAN REPRODUCTION, 1995, 10 (12) :3102-3106
[94]  
HERMAN A, 1990, FERTIL STERIL, V53, P92
[95]  
HUGHES E, 2000, COCHRANE DB SYST REV
[96]   Preventing OHSS in at-risk patients: evidence from a long-term prospective study [J].
Imoedemhe, D ;
Chan, R ;
Pacpaco, E ;
Olazo, A ;
Avila, F ;
Holiva, N ;
Masangcay, M .
HUMAN REPRODUCTION, 1999, 14 :102-103
[97]   A NEW APPROACH TO THE MANAGEMENT OF PATIENTS AT RISK OF OVARIAN HYPERSTIMULATION IN AN INVITRO FERTILIZATION PROGRAM [J].
IMOEDEMHE, DAG ;
CHAN, RCW ;
SIGUE, AB ;
PACPACO, ELA ;
OLAZO, AB .
HUMAN REPRODUCTION, 1991, 6 (08) :1088-1091
[98]   Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome [J].
Isik, AZ ;
Vicdan, K .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 97 (02) :208-212
[99]   Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: A prospective, randomized and controlled study [J].
Isik, AZ ;
Gokmen, O ;
Zeyneloglu, HB ;
Kara, S ;
Keles, G ;
Gulekli, B .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1996, 70 (02) :179-183
[100]   USE OF GONADOTROPIN-RELEASING-HORMONE AGONIST TO CAUSE OVULATION AND PREVENT THE OVARIAN HYPERSTIMULATION SYNDROME [J].
ITSKOVITZELDOR, J ;
LEVRON, J ;
KOL, S .
CLINICAL OBSTETRICS AND GYNECOLOGY, 1993, 36 (03) :701-710